-
Mashup Score: 5
Nature Reviews Clinical Oncology – Zanidatamab shows promise as first-line therapy for advanced-stage HER2+ GEA
Source: www.nature.comCategories: General Medicine NewsTweet
-
Mashup Score: 5Second-line tarlatamab improves OS in SCLC - 19 day(s) ago
Nature Reviews Clinical Oncology – Second-line tarlatamab improves OS in SCLC
Source: www.nature.comCategories: General Medicine NewsTweet
-
Mashup Score: 1
Nature Reviews Clinical Oncology – Robot-assisted laparoscopic surgery confers improved oncological outcomes
Source: www.nature.comCategories: General Medicine NewsTweet
-
Mashup Score: 2
Nature Reviews Clinical Oncology – Adding durvalumab to perioperative FLOT improves gastric cancer outcomes
Source: www.nature.comCategories: General Medicine NewsTweet
-
Mashup Score: 9The next generation of immunotherapies for lung cancers - 19 day(s) ago
Nature Reviews Clinical Oncology – Immune-checkpoint inhibitors (ICIs) have improved lung cancer outcomes, although resistance to these agents presents a substantial challenge. This Review…
Source: www.nature.comCategories: General Medicine NewsTweet
-
Mashup Score: 43
Nature Reviews Clinical Oncology – Liquid biopsy-based tests have demonstrated potential as a minimally invasive and broadly applicable approach to simultaneously screen individuals for multiple…
Source: www.nature.comCategories: General Medicine NewsTweet
-
Mashup Score: 13
Nature Reviews Clinical Oncology – Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC
Source: www.nature.comCategories: General Medicine NewsTweet
-
Mashup Score: 13
Nature Reviews Clinical Oncology – Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC
Source: www.nature.comCategories: General Medicine NewsTweet
-
Mashup Score: 1T-DXd effective as second-line therapy in G/GEJ cancers - 24 day(s) ago
Nature Reviews Clinical Oncology – T-DXd effective as second-line therapy in G/GEJ cancers
Source: www.nature.comCategories: General Medicine NewsTweet
-
Mashup Score: 4A new first-line standard-of-care for BRAFV600E-mutated mCRC - 24 day(s) ago
Nature Reviews Clinical Oncology – A new first-line standard-of-care for BRAFV600E-mutated mCRC
Source: www.nature.comCategories: General Medicine NewsTweet
New online! Zanidatamab shows promise as first-line therapy for advanced-stage HER2+ GEA https://t.co/fl2gFcvTAB